At issue were claims that Moderna had infringed on patents owned by Genevant and Arbutus related to lipid nanoparticles, or tiny bubbles of fat that Moderna used to deliver its Covid-19 shot inside patients.
(March 4): Moderna Inc agreed to pay US$950 million to settle litigation related to the delivery technology behind its Covid-19 shot, removing a looming financial risk for the struggling vaccine maker.
The company has settled all litigation worldwide with Arbutus Biopharma Corp and Genevant Sciences GmbH over its existing and future vaccines, with no future royalties owed.
